A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. UroGen Pharma Ltd’s current trading price is -47.73% away from its 52-week high, while its distance from the 52-week low is 5.46%. The stock’s price range for this time frame has been between $10.26 and $20.70. The trading volume of the company’s shares in the Healthcare reached around 0.23 million for the day, which was evidently lower than the average daily volume of 0.53 million over the last three months.
UroGen Pharma Ltd had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $20.70 on 06/14/24, while the lowest price during the same period was $10.26 on 12/23/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
UroGen Pharma Ltd (URGN) has experienced a quarterly decline of -15.86% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 456.60M and boasts a workforce of 201 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 12.81, with a change in price of -4.86. Similarly, UroGen Pharma Ltd recorded 529,561 in trading volume during the last 100 days, posting a change of -30.99%.
How URGN’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for URGN stands at 4.81. Similarly, the long-term debt-to-equity ratio is also 4.78.
URGN Stock Stochastic Average
UroGen Pharma Ltd’s raw stochastic average for the past 50 days is currently at 17.07%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 19.49%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 13.37% and 9.55%, respectively.
URGN Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The metric has seen a significant loss of -27.87% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -37.02%. Over the past 30 days, the price of URGN has leaped by -9.15%. And in the last five days, it has fallen by -4.50%.
